Braveheart Bio Raises $185 Million Series A to Advance Global Development of HCM Therapy BHB‑1893
Braveheart Bio, a late clinical-stage biotechnology company focused on developing novel therapies for hypertrophic cardiomyopathy (HCM) and related cardiovascular diseases, has launched with a sizable $185 million Series A financing round that positions the company for global late-stage development of its lead therapeutic candidate, BHB‑1893. The funding round reflects strong investor confidence in the company’s scientific strategy and the market opportunity for improved treatments for HCM, a genetic heart condition that affects about 1 in 500 people worldwide.
The $185 million Series A financing was led by Andreessen Horowitz (a16z Bio + Health), one of the most active life sciences venture capital firms investing in transformative therapeutics and biotechnology. Other major participants in the round included Forbion, a European life sciences investor focused on paradigm-shifting innovation in medicine; OrbiMed, a global healthcare investment firm with a broad portfolio across private and public biotech companies; Enavate Sciences, a platform of Patient Square Capital dedicated to life sciences ventures; and Frazier Life Sciences, an investor targeting breakthrough biopharmaceutical and medical technology companies.
Braveheart Bio’s Series A financing accompanies its official launch as a company with a focused mission: advancing its selective cardiac myosin inhibitor BHB‑1893 through global late-stage clinical development. This small-molecule therapeutic candidate, engineered to reduce excessive cardiac muscle contraction, has already undergone extensive clinical development, including Phase 2 dose-ranging studies in symptomatic obstructive HCM and ongoing Phase 2 studies in non-obstructive HCM. A Phase 3 study in obstructive HCM is also underway in China, and the company plans to launch global late-stage development in 2026.
Braveheart’s leadership team brings deep expertise in cardiovascular medicine and biotech company building. Travis Murdoch, MD, President and Chief Executive Officer, leads the company’s strategy to establish BHB‑1893 as a potential best-in-class therapy for HCM — aiming to improve outcomes for patients with limited options under current standards of care. The company’s board includes seasoned life science executives, with Chris Viehbacher serving as Chair, reflecting a governance structure designed to support aggressive clinical and commercial progress.
The Series A capital will primarily support Braveheart Bio’s push to complete global late-stage clinical trials, expand its research and development operations, and prepare for potential regulatory submissions in multiple regions. The financing also positions Braveheart to build out its commercial and medical affairs capabilities ahead of anticipated market entry if clinical data supports regulatory approval.
A key strategic element of Braveheart Bio’s formation includes its licensing agreement with Jiangsu Hengrui Pharmaceuticals, under which Braveheart obtained exclusive global rights — outside of mainland China, Hong Kong, Macau and Taiwan — to develop, manufacture and commercialize HRS‑1893, the small-molecule cardiac myosin inhibitor that forms the basis of BHB‑1893. Under the terms of that deal, Braveheart made an upfront payment of $65 million (split between cash and company shares), with additional payments tied to technology transfer completion and future milestones that could exceed $1 billion, including royalties on product sales.
Investors in the Series A round have emphasized the urgent need for innovative therapies in cardiovascular disease and the confidence they see in Braveheart Bio’s scientific and clinical thesis. With BHB‑1893 showing early clinical promise in reducing left ventricular outflow tract gradients and with a safety profile that supports a straightforward dosing regimen, the company is poised to compete in a therapeutic landscape that includes other cardiac myosin inhibitors under development.
Braveheart Bio’s substantial new funding and strategic partnerships position it to accelerate development of its lead program and explore additional opportunities to address unmet needs in cardiovascular medicine. As the company advances toward global clinical milestones, its investor backing and leadership team aim to establish Braveheart Bio as a significant player in the future of HCM treatment and broader cardiometabolic therapeutic innovation.
